Cytotoxic activity of azulenequinones against human oral tumor cell lines by 若林, 英嗣 et al.
Abstract. We investigated twenty-seven azulenequinone
derivatives for their relative cytotoxicity against three human
normal cell lines (HGF, HPC, HPLF) and four human tumor
cell lines (HSG, HSC-2, HSC-3, HL-60). Parent 1,5-
azulenequinone showed potent and some tumor-specific
cytotoxicity. Halogenated derivatives of 1,5- and 1,7-
azulenequinone showed potent cytotoxicity, but lower tumor-
specific cytotoxicity. In contrast to other azulenequinones,
amino derivatives such as 3-amino-1,5- and 1,7-
azulenequinones showed relatively lower cytotoxic activity. The
3-Phenoxy-1,5-azuleneqinone derivative showed higher
cytotoxicity than the 3-phenoxy-1,7-azulenequinone derivative.
1,5- and 1,7-Azulenequinones generally showed higher
cytotoxicity, as compared with tropolones and azulene
derivatives. 3-(3-Guaiazulenyl)-1,5-azulenequinone [12] and
7-isopropyl-3-(4-methylanilino)-2-methyl-1,5-azulenequinone
[24] showed a relatively higher TS value and induced
apoptosis (internucleosomal DNA fragmentation, activation of
caspases 3, 8 and 9) in HL-60 and HSC-2 cells, possibly via
the activation of both mitochondria-independent (extrinsic)
and -dependent (intrinsic) pathways. Western blot analysis
showed that [24] slightly increased the intracellular
concentration of pro-apoptotic proteins (Bad, Bax) in HSC-2
cells, whereas [12] was much less active. None of the twenty-
seven azulenequinones showed anti-HIV activity. These results
suggest [12] and [24] as possible candidates for future cancer
chemotherapy. 
Azulene derivatives (1-4) have shown several biological
activities, including antibacterial activity (5), anti-ulcer
activity (6), relaxant activity (7), inhibition of thromboxane
A2-induced vasoconstriction and thrombosis (8), acute
toxicity and local anesthetic activity (9), and possible
chemotherapeutic activity for mucous membrane diseases
(10, 11). However, the effects of azulene derivatives on
cellular function have not been investigated in detail.  We
have recently reported that methyl 7-isopropyl-2-
methoxyazulene-1-carboxylate induced tumor-specific
cytotoxicity and apoptotic cell death (characterized by
internucleosomal DNA fragmentation and caspase 3
activation) in HL-60 cells, without involvement of the
radical-mediated oxidation mechanism (12).
On the other hand, azulenequinone is a nonbenzenoid
aromatic quinone (13, 14) and also an isomer of
naphthoquinone. Naphthoquinones have shown antifungal,
antibiotic, antimalarial, or antitumor activity (15). 
We investigated, here, whether a total of twenty-seven
azulenequinone derivatives (structure shown in Figure 1)
display tumor-specific cytotoxic activity, using three normal
human cell lines [gingival fibroblast (HGF), pulp cell (HPC),
periodontal ligament fibroblast (HPLF)] and four human
tumor cell lines [submandibular gland carcinoma (HSG), oral
squamous cell carcinoma (HSC-2, HSC-3), promyelocytic
leukemia (HL-60)], and, if so, whether azulenequinones
induce apoptosis-associated characteristics (such as DNA
fragmentation and caspase activation) in human tumor cells.
Materials and Methods
Methods. The following chemicals and reagents were obtained from
the indicated companies: Dulbeccos’s modified Eagle medium
(DMEM) (Gibco BRL, Grand Island, NY, USA); fetal bovine
serum (FBS)(JRH, Bioscience, Lenexa, KS, USA); dimethyl
sulfoxide (DMSO), diethylenetriaminepentaacetic acid
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(DETAPAC) (Wako Pure Chem, Ind, Ltd, Osaka, Japan); RPMI
1640, 3-(4,5-dimethylthiazol-2-yl)-2,2-diphenyltetrazolium bromide
(MTT), 3’-azido-2’, 3’-dideoxythymidine (AZT), dideoxycytidine
(ddC) (Sigma Chem Co., St. Louis, MO, USA).
Synthesis of azulenequinone derivatives. Azulenequinone derivatives
were synthesized, according to the published reports: 1,5-
azulenequinone [1] (16-21), 3-chloro-1,5-azulenequinone [2]
(19,21,22), 3-bromo-1,5-azulenequinone [3] (19,21,23), 3-iodo-1,5-
azulenequinone [4] (19,21,22), 3-phenoxy-1,5-azulenequinone [5]
(19,24), 3-(4-nitrophenoxy)-1,5-azulenequinone [6] (19,24), 3-
(N,N-dimethylamino)-1,5-azulenequinone [7] (19,24), 3-
morpholino-1,5-azulenequinone [8] (19,24) 3-(2-
hydroxyethylamino)-1,5-azulenequinone [9] (19,24) 3-(4-
methoxyanilino)-1,5-azulenequinone [10] (19,24), 3-(1-azulenyl)-
1,5-azulenequinone [11] (19,24), 3-(3-guaiazulenyl)-1,5-
azulenequinone [12] (19,24), 3,7-dibromo-1,5-azulenequinone [13]
(19,21,23), 3-bromo-1,7-azulenequinone [14] (19,21,23), 3-iodo-
1,7-azulenequinone [15] (19,21,22), 3-(4-nitrophenoxy)-1,7-
azulenequinone [16] (19,24), 3-(N,N-dimethylamino)-1,7-
azulenequinone [17] (19,24), 3-morpholino-1,7-azulenequinone
[18] (19,24), 3-(4-methoxyanilino)-1,7-azulenequinone [19]
(19,24), 3-bromo-2-methyl-1,5-azulenequinone [20] (19,20), 3-
bromo-2-methoxy-1,5-azulenequinone [21] (19,25), 3-bromo-4,6,8-
trimethyl-1,5-azulenequinone [22] (19,26), 3-(N,N-dimethylamino)-
5-isopropyl-1,7-azulenequinone [23] (19), 7-isopropyl-3-(4-
methylanilino)-2-methyl-1,5-azulenequinone [24] (19), 7-isopropyl-
3-(N,N-dimethylamino)-1,5-azulenequinone [25] (19), 7-isopropyl-
3-morpholino-1,5-azulenequinone [26] (19,27), 3-(2-
hydroxyethylamino)-7-isopropyl-1,5-azulenequinone [27] (19,27).
Cell culture. Three human oral tumor cell lines (HSG, HSC-2,
HSC-3) and three human normal cells [HGF (5-8 population
doubling level (PDL)), HPC (5-8PDL), HPLF (5-8PDL)] were
cultured in DMEM supplemented with 10% heat-inactivated FBS.
Human promyelocytic leukemic HL-60 cells were cultured in
RPMI 1640 supplemented with 10% heat-inactivated FBS. Tumor
cell lines were obtained from the Riken Cell Bank. Normal cells
were prepared from periodontal tissues, according to the guideline,
of Meikai University Ethic Committee, Japan, (No. 0206) after
obtaining informed consent from the patients.
Assay for cytotoxic activity. Cells (other than HL-60 cells) were
inoculated at 12 x 103 cells/well in 96-microwell (Becton Dickinson
Labware, NJ, USA), unless otherwise stated. After 24 hours, the
medium was removed by suction with an aspirator, and replaced with
0.1 mL of fresh medium containing various concentrations of test
compounds. Cells were incubated for another 24 hours, and the
relative viable cell number was then determined by MTT method. 
In brief, cells were replaced with fresh culture medium containing
0.2 mg/mL MTT and incubated for another 4 hours. The cells were
lysed with 0.1 mL of DMSO, and the absorbance at 540 nm of the
cell lysate was determined, using a microplate reader (Biochromatic
Labsystem, Helsinki, Finland) (28). A540 of control cells were usually
in the range from 0.40 to 0.90. The 50% cytotoxic concentration
(CC50) was determined from the dose-response curve. Tumor-
specificity (TS) was determined by the following equation:
CC50 (HGF)+ CC50 (HPC)+ CC50 (HPLF) 4
TS= --------------------------------------------------------------------------------------------------------------------------- x ---------
CC50 (HSG)+CC50 (HSC-2)+CC50 (HSC-3)+CC50(HL-60) 3
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Figure 1. Structure of azulenequinone derivatives.
The viability of HL-60 cells was determined by trypan blue
exclusion, under a light microscope. HL-60 cells were inoculated
at 5 x 104/0.1 mL in 96-microwell, and various concentrations of
test compounds added. After incubation for 24 hours, the viable
cell number was determined as described above. The cell density
of control cells at cell harvest was in the range of 8 - 9 x 105/mL.
Assay for DNA fragmentation. Cells were lysed with 50 ÌL lysate
buffer (50 mM Tris-HCl, pH 7.8, 10 mM EDTA, 0.5% (w/v)
sodium N-lauroylsarcosinate), and incubated for 2 hours at 50ÆC
with 0.4 mg/mL RNase A and 0.8 mg/mL proteinase K (29).
DNA was extracted with phenol-chloroform-isoamylalcohol
(25:24:1), and precipitated with ethanol. DNA was dissolved in
TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5), and applied
to 2% agarose gel electrophoresis in TBE buffer (89 mM Tris-
HCl, 89 mM boric acid, 2 mM EDTA, pH 8.0). ∞ DNA
molecular marker (Bayou Biolabs, Harahan, LA, USA) and
DNA from apoptotic HL-60 cells induced by actinomycin D
(1Ìg/mL) were run in parallel (29). After staining with ethidium
bromide, DNA was visualized by UV irradiation, and
photographed by CCD camera (Bio Doc Inc, UVP).
Assay for caspase activation. Cells were washed with PBS and lysed
in lysis solution (MBL, Nagoya, Japan). After standing for 10
minutes on ice and centrifugation for 5 minutes at 10,000 xg, the
supernatant was collected. Lysate (50 ÌL, equivalent to 200 Ìg
protein) was mixed with 50 ÌL 2x reaction buffer (MBL) containing
substrates for caspase 3 (DEVD-pNA (p-nitroanilide)) , caspase 8
(IETD-pNA) or caspase 9 (LEHD-pNA). After incubation for 2
hours at 37ÆC, the absorbance at 405 nm of the liberated
chromophore pNA was measured by plate reader. 
Western blotting. The cells were lysed with 100 ÌL of lysis buffer
(10 mM Tris-HCl, pH 7.6, 1% Triton X-100, 150 mM NaCl, 5 mM
EDTA and 2 mM PMSF) for 10 minutes in ice water, and then
incubated for 50 minutes at 4ÆC with RT-5 ROTATOR (Titec,
Saitama, Japan). Cell lysates were centrifuged at 16,000 xg for 20
minutes at 4ÆC to remove insoluble materials and the supernatant
was collected. The protein concentration of the supernatant was
determined by Protein Assay Kit (Bio Rad, Hercules, CA, USA).
Cell lysates (containing 15 Ìg protein) were mixed with 2 x sodium
dodecyl sulfate (SDS)-sample buffer (0.1 M Tris-HCl, pH 6.8, 20%
glycerol, 4% SDS, 0.01% bromphenol blue, 1.2% 2-
mercaptoethanol), boiled for 10 minutes, and applied to SDS-12%
polyacrylamide gel electrophoresis, and then transferred to
polyvinylidene difluoride (PVDF) membrane. The mebranes were
blocked with 5% skim milk in phosphate-buffered saline (PBS)
plus 0.05% Tween 20 overnight at 4ÆC and incubated with anti-
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Table I. Cytotoxic activity of azulenequinones.
Cytotoxic activity (CC50:ÌM)
Normal human cells Human tumor cell lines
Compd. MW HGF HPC HPLF HSG HSC-2 HSC-3 HL-60 TS
1 158.16 30.6 37.3 25.5 8.9 <6.2 17.2 <3.9 >3.4
2 192.6 10.9 13.8 4.0 4.7 <4.0 18.0 <3.9 >1.3
3 237.05 54.4 22.0 15.3 17.9 <17.6 19.7 <3.9 >2.1
4 284.05 <9.1 17.8 12.1 6.0 6.7 7.8 <4.9 ><2.1
5 250.26 127.0 29.0 23.5 11.3 2 .2 10.6 <4.2 >8.5
6 295.25 90.4 40.8 22.2 14.5 <3.9 21.8 <5.7 >4.5
7 201.25 406.0 294.0 >500.0 145.0 58.8 162.9 103.5 >3.4
8 243.26 114.0 314.0 >500.0 173.3 22.3 74.8 102.0 >3.3
9 217.22 >500.0 >500.0 >500.0 >500.0 52.3 >500.0 >500.0 ><1.3
10 279.3 N.D. 275.0 200.0 90.0 27.2 200.0 >452.0 1.2
11 284.31 243.0 >500.0 >500.0 >500.0 117.0 309.4 40.5 ><1.7
12 354.45 51.6 500.0 93.8 47.0 117.0 50.3 7.5 3.9
13 315.95 51.3 61.6 53.3 35.0 21.3 52.2 <3.9 >2.0
14 237.05 45.2 52.6 52.4 20.5 33.2 39.2 <4.0 >2.1
15 284.05 64.3 30.8 26.5 15.5 36.2 25.4 <4.9 >2.0
16 295.25 20.3 250.0 130.0 89.2 69.8 131.8 <26.0 >1.7
17 201.23 359.0 >500.0 >500.0 >500.0 347.0 >500.0 >497.5 ><1.0
18 243.26 241.0 >500.0 >500.0 >500.0 232.0 456.0 >372.0 ><1.1
19 279.3 214.0 500.0 188.0 >500.0 15.4 40.6 >439.0 <1.2
20 251.08 10.2 21.8 19.6 15.2 22.1 25.1 <4.4 >1.0
21 267.08 5.5 14.0 9.8 6.0 10.9 16.9 <3.7 >1.0
22 279.13 26.0 37.0 41.2 21.9 28.4 36.9 5.9 1.5
23 243.3 95.4 487.0 400.0 370.0 289.0 311.6 306.0 1.0
24 319.4 104.0 500.0 500.0 57.1 6.5 35.2 46.0 10.2
25 243.3 63.7 327.0 410.0 128.4 112.0 230.2 121.0 1.8
26 285.34 304.0 201.0 300.0 69.3 21.6 65.7 50.0 5.2
27 259.3 111.0 >500.0 471.0 293.8 207.0 324.9 244.0 >1.3
N.D., not determined due to the coloration.
Bcl-2 antibody (1:1,000), anti-Bax antibody (1:1,000), anti-Bad
antibody (1:1,000) (Santa Cruz Biotechnology, Delaware, CA,
USA) or anti-actin antibody (1:1,000) (Sigma) for 90 minutes at
room temperature, and then incubated with horseradish
peroxidase-conjugated anti-rabbit IgG for 1 hour at room
temperature. Immunoblots were developed by Western
Lightningì Chemiluminescence Reagent Plus (Perkin Elmer Life
Sciences, Boston, MA, USA), and analyzed on a Macintosh
(Power Macintosh 7600/120) computer, using the public domain
NIH Image Program (developed at the U.S. National Institute of
Health and available from the Internet by anonymous FTP from
zippy.nimh.nih.gov or on floppy disk from the National Technical
Information Service, Springfield, Virginia, USA, part number
PB95-500195GEI).
Assay for anti-human immunodeficiency virus (HIV) activity. MT-4 cells
were infected with HIV-1IIIB at a multiplicity of infection (m.o.i.) of
0.01. HIV- or mock- infected (control) MT-4 cells (1.5 x 105/mL, 200
ÌL/well) were placed into 96-well microtiter plates and incubated in
the presence of various concentrations of test samples. After
incubation for 5 days at 37ÆC in a 5% CO2 incubator, cell viability
was quantified by a colorimetric assay (at 540 nm and 690 nm),
monitoring the ability of viable cells to reduce MTT to a blue
formazan product. The CC50 and 50% effective concentration (EC50)
were determined from the dose-response curve with mock-infected or
HIV-infected cells, respectively (30). All data represent the mean values
of triplicate measurements. The anti-HIV activity was evaluated by
selectivity index (SI), which was calculated by the following equation:
SI=CC50/EC50
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Figure 2. Induction of DNA fragmentation by [12] and [24]. Near confluent HL-60 (A) and HSC-2 (B) cells were incubated for 6 hours with the indicated
concentrations of 3-(3-guaiazulenyl)-1,5-azulenequinone [12], 7-isopropyl-3-(4-methylanilino)-2-methyl-1,5-azulenequinone [24] or with 1 Ìg/mL
actinomycin D (Act-D). DNA was then extracted and applied to agarose gel electrophoresis. Marker DNA was run in lane 1.
Results and Discussion
Structure and activity relationship. We investigated twenty-
seven azulenequinone derivatives for their relative
cytotoxicity against three human normal cells (HGF, HPC,
HPLF) and four human tumor cell lines (HSG, HSC-2,
HSC-3, HL-60) (Table I). 
1,5-Azulenequinone [1], a parent compound, showed
potent (mean CC50 for four tumor cells (MCT= <9.1 ÌM)
and some tumor-specific cytotoxicity (TS=>3.4) (Table I). 
Halogenated derivatives of 1,5- and 1,7-azulenequinone
[2, 3, 4, 13, 14, 15, 20, 21, 22] showed potent cytotoxicity
(MCT=<7.7, <14.8, <6.4, <28.1, <24.2, <20.5, <16.7, 9.4
and 23.3 ÌM, respectively), but lower tumor-specific
cytotoxicity (TS=>1.3, >2.1, ><2.1, >2.0, >2.1, >2.0,
>1.0, >1.0 and 1.5, respectively). 
In contrast to other azulenequinones, amino derivatives
such as 3-amino-1,5- [7, 8, 9, 10, 25, 26, 27] (MCT=117.6,
93.1, >388, >192.3, 147.9, 51.7 and 26.7.4 ÌM, respectively)
and 3-amino-1,7-azulenequinones [17, 18, 19, 23]
(MCT=>461.1, >390.0, >248.8 and 319.2 ÌM, respectively)
showed relatively lower cytotoxic activity.
3-Phenoxy-1,5-azulenequinone derivatives [5, 6]
(MCT=<7.1 and <11.5 ÌM, respectively) showed higher
cytotoxicity than the derivative [16] (MCT=<79.2 ÌM).
1,5- and 1,7-Azulenequinones generally showed higher
cytotoxicity, as compared with tropolones (31) and azulene
derivatives (8).
3-Phenoxy-1,5-azulenequinone [5], 3-(4-nitrophenoxy)-1,5-
azulenequinone [6], 3-(3-guaiazulenyl)-1,5-azulenequinone
[12], 7-isopropyl-3-(4-methylanilino)-2-methyl-1,5-azulen-
equinone [24] and 7-isopropyl-3-morpholino-1,5-azulen-
Wakabayashi et al: Cytotoxicity of Azulenequinones
309
Figure 3. Activation of caspases 3, 8 and 9 by [12] and [24]. HL-60 (A, B) and HSC-2 (C, D) cells were incubated for 4 hours without (control) or with
3-(3-guaiazulenyl)-1,5-azulenequinone [12] (A, C), 7-isopropyl-3-(4-methylanilino)-2-methyl-1,5-azulenequinone [24] (B, D) Act-D: 1 Ìg/mL
actinomycin D was included in each group of figures as positive control. 
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Figure 4. Effect of [12] and [24] on the intracellular concentration of
apoptosis-related proteins. Near confluent HL-60 and HSC-2 cells were
incubated for 4 hours with the indicated concentrations of [12] or [24].
Cell lysate (equivalent to 15 Ìg/mL) was subjected to Western blot analysis
with respective antibodies. The intracellular concentration of Bad, Bax and
Bcl-2 was quantitated and expressed as the ratio to that of Actin, and the
control level of these proteins was normalized to 1.0.
equinone [26] showed relatively higher TS value (>8.5, >4.5,
3.9, 10.2 and 5.2, respectively).  
Apoptosis induction. Figure 2A shows that both [12] and
[24] induced the internucleosomal DNA fragmentation, a
biochemical hallmark of apoptosis, in HL-60 cells. The
optimal concentrations of these compounds were 16 and
160 ÌM, respectively. However, neither of these compounds
induced internuclesomal DNA fragmentation in HSC-2
cells (Figure 2B).
Figure 3A and B show that [12] and [24] activated
caspases 3, 8 and 9 in HL-60 cells, to a level slightly lower
than that attained by actinomycin D (1 Ìg/mL), a positive
control. The optimal concentrations of these compounds
were 32 and 160 ÌM, respectively.  Figure 3C shows that [12]
also activated caspases 3, 8 and 9 in HSC-2 cells, but required
higher concentrations. Figure 3D shows that [24] activated
these caspases, but to a much lesser extent than that attained
by actinomycin D. 
We next investigated the possible changes in the
intracellular concentrations of pro-apoptotic proteins
(Bad, Bax) and anti-apoptotic protein (Bcl-2) by Western
blot analysis. Figure 4 shows that [24] slightly reduced
the concentrations of Bcl-2 in HL-60 cells, whereas [12]
was much less active. [24] elevated the concentrations of
Bad and Bax more potently than [12] in HSC-2 cells. Bcl-
2 could not be detected in HSC-2 cells with or without
treatment (data not shown). The apoptosis-inducing
activity of other compounds [5, 6, 26] will be reported
elsewhere. 
Anti-HIV activity. None of the twenty-seven azulenequiones
showed anti-HIV activity (SI<1), in contrast to the potent
anti-HIV activity of AZT (SI=6367) and ddC (SI=808),
positive controls (Table II). 
We found, for the first time, that among twenty-seven
azulenequinone derivatives, 3-(3-guaiazulenyl)-1,5-
azulenequinone [12] and 7-isopropyl-3-(4-methylanilino)-
2-methyl-1,5-azulenequinone [24] showed both higher
tumor-specific cytotoxic activity and apoptosis. These
compounds activated both the mitochondria-independent
extrinsic pathway (involved with caspase 8) and the
mitochondria-dependent intrinsic pathway (involved with
caspase 9) (32). This finding is important, since the
apoptosis-inducing agents (‚-diketones, ·,‚-unsaturated
ketones, hydroxylketones) do not always show tumor-
specific cytotoxicity and compounds with higher tumor-
specificity do not always induce apoptosis (33-35). Further
study is required to elucidate the molecular mechanism of
apoptosis induction by these azulenequinones. We have
recently found that azulenes and tropolones inhibited the
NO production by LPS-stimulated mouse macrophage-
like Raw 264.7 cells (36, 37). It remains to be investigated
whether azulenequinones also inhibit the NO production
by activated macrophages.
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